Children's Preferences for Oral Dosage Forms and Their Involvement in Formulation Research via EPTRI (European Paediatric Translational Research Infrastructure).
EPTRI
medicines acceptability
oral dosage forms
paediatric formulations
patient-centric research
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
15 May 2021
15 May 2021
Historique:
received:
30
03
2021
revised:
08
05
2021
accepted:
11
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
The paucity of evidence-based data on formulation characteristics preferred by the children is known to limit the design of tailored paediatric dosage forms. The European Paediatric Translational Research Infrastructure (EPTRI) commissioned a study to evaluate children's dosage forms perceived preferences in some European countries and explore the feasibility of using the young persons advisory groups (YPAGs) to involve children in formulation research. An online, age-adapted survey was developed and translated into six languages. The survey link was disseminated across seven European countries: Albania, Italy, the Netherlands, and Dutch-speaking part of Belgium, Romania, Spain, and the United Kingdom. Respondents' (
Identifiants
pubmed: 34063499
pii: pharmaceutics13050730
doi: 10.3390/pharmaceutics13050730
pmc: PMC8156390
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Horizon 2020 Framework Programme
ID : 777554
Références
Int J Pharm. 2016 Nov 30;514(1):296-307
pubmed: 27863675
Arch Dis Child. 2016 Sep;101(9):785-7
pubmed: 27117837
Int J Pharm. 2014 Aug 5;469(2):245-8
pubmed: 24704104
Drug Deliv. 2017 Nov;24(1):1243-1248
pubmed: 28856931
Int J Pharm. 2018 Feb 5;536(2):547-562
pubmed: 28705619
Sci Rep. 2018 Jun 15;8(1):9210
pubmed: 29907752
Eur J Pharm Biopharm. 2020 Jun;151:239-245
pubmed: 32348882
J Pharm Pharmacol. 2017 Apr;69(4):361-376
pubmed: 27524471
Drugs. 2014 Oct;74(16):1871-1889
pubmed: 25274536
BMJ. 2020 Oct 5;371:m3550
pubmed: 33020053
J Pediatr. 2013 Dec;163(6):1728-1732.e1
pubmed: 23972645
Int J Pharm. 2011 Oct 31;419(1-2):235-9
pubmed: 21784141
Int J Pediatr Adolesc Med. 2020 Dec;7(4):166-173
pubmed: 33319014
BMJ Open. 2020 Oct 10;10(10):e036508
pubmed: 33039988
Bull World Health Organ. 2017 Mar 1;95(3):238-240
pubmed: 28250539
J Pediatr. 2018 Oct;201:202-207.e1
pubmed: 29960767
Br J Clin Pharmacol. 2014 Nov;78(5):1080-9
pubmed: 24965935
Int J Pharm. 2020 Jul 30;585:119511
pubmed: 32522503
Arch Dis Child. 2020 Nov;105(11):1105-1107
pubmed: 31594776
Fundam Clin Pharmacol. 2018 Aug;32(4):357-362
pubmed: 29457267
AAPS J. 2016 Sep;18(5):1047-1055
pubmed: 27317470
Pediatrics. 2009 Feb;123(2):e235-8
pubmed: 19171575
Int J Pharm. 2012 Oct 5;435(2):134-5
pubmed: 22883696
Clin Pharmacol Ther. 2013 Nov;94(5):582-4
pubmed: 23892403
Arch Dis Child. 2012 Mar;97(3):283-6
pubmed: 22253279
J Pediatr. 2015 Oct;167(4):893-896.e2
pubmed: 26259675